Last reviewed · How we verify
Combination of chemotherapy and immunotherapy
Combination of chemotherapy and immunotherapy is a Small molecule drug developed by Guangzhou University of Traditional Chinese Medicine. It is currently in Phase 1 development.
At a glance
| Generic name | Combination of chemotherapy and immunotherapy |
|---|---|
| Sponsor | Guangzhou University of Traditional Chinese Medicine |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Fatigue
- Diarrhoea
- Nausea
- Anaemia
- Decreased appetite
- Alopecia
- Asthenia
- Constipation
- Arthralgia
- Hypertension
- Oedema peripheral
- Neutropenia
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy (PHASE2)
- Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer (PHASE2)
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
- Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (PHASE3)
- Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma (PHASE1)
- MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Combination of chemotherapy and immunotherapy CI brief — competitive landscape report
- Combination of chemotherapy and immunotherapy updates RSS · CI watch RSS
- Guangzhou University of Traditional Chinese Medicine portfolio CI
Frequently asked questions about Combination of chemotherapy and immunotherapy
What is Combination of chemotherapy and immunotherapy?
Combination of chemotherapy and immunotherapy is a Small molecule drug developed by Guangzhou University of Traditional Chinese Medicine.
Who makes Combination of chemotherapy and immunotherapy?
Combination of chemotherapy and immunotherapy is developed by Guangzhou University of Traditional Chinese Medicine (see full Guangzhou University of Traditional Chinese Medicine pipeline at /company/guangzhou-university-of-traditional-chinese-medicine).
What development phase is Combination of chemotherapy and immunotherapy in?
Combination of chemotherapy and immunotherapy is in Phase 1.
What are the side effects of Combination of chemotherapy and immunotherapy?
Common side effects of Combination of chemotherapy and immunotherapy include Fatigue, Diarrhoea, Nausea, Anaemia, Decreased appetite, Alopecia.